Named Bioactive Compounds · Compound
Tetramethylpyrazine (Alkaloid)
Moderate Evidencealkaloid
Hermetica Superfood Encyclopedia
Tetramethylpyrazine is a bioactive alkaloid compound extracted from Ligusticum chuanxiong that demonstrates neuroprotective and cardiovascular effects. The compound works primarily through antioxidant activity and platelet aggregation inhibition mechanisms.
Tetramethylpyrazine (TMP), also known as ligustrazine, is an alkylpyrazine alkaloid primarily isolated from the rhizome of the Chinese medicinal herb Ligusticum wallichii (Chuan Xiong). It also occurs naturally in fermented foods like nattō and cocoa beans, and is extracted using chromatography techniques to yield a colorless solid with the chemical formula C₈H₁₂N₂.
Current evidence for tetramethylpyrazine is limited to preclinical studies in animal models and cell cultures, with no human clinical trials, RCTs, or meta-analyses identified in the research dossier. Studies have focused on neuroprotective effects in rodent Alzheimer's models and anti-inflammatory mechanisms in rat studies, but lack human trial data including sample sizes, outcomes, or PMIDs.
No clinically studied dosage ranges for tetramethylpyrazine have been established in human trials. The research mentions oral and intravenous administration routes in animal studies without specific dosing recommendations or standardization details. Consult a healthcare provider before starting any new supplement.
Tetramethylpyrazine (TMP), also known as ligustrazine, is a bioactive alkaloid compound (molecular formula: C₈H₁₂N₂, MW: 136.19 g/mol) rather than a food with a broad nutritional profile. Key details: • **Chemical identity**: 2,3,5,6-tetramethylpyrazine; a pyrazine-class alkaloid naturally occurring in fermented foods and traditional medicinal plants. • **Natural sources & approximate concentrations**: Found in Ligusticum chuanxiong (Szechuan lovage rhizome) at ~0.1–1.5 mg/g dried herb; present in fermented cocoa beans (~0.5–5 µg/g), natto (fermented soybean, trace–low µg/g range), certain aged vinegars, Bacillus subtilis-fermented products, and roasted/fermented grain-based foods where it forms via Maillard reactions and microbial metabolism. • **Primary bioactive compound**: TMP itself is the principal bioactive; it is a low-molecular-weight lipophilic alkaloid with notable blood-brain barrier permeability (logP ~1.28), contributing to its CNS bioactivity. • **Bioavailability notes**: Oral bioavailability in animal models is moderate (~20–45% in rats) due to rapid first-pass hepatic metabolism; plasma half-life is short (~0.5–2.5 hours in rodents). Peak plasma concentration (Tmax) reached within 0.5–1 hour orally. TMP is primarily metabolized via hepatic CYP450 oxidation to hydroxylated and demethylated metabolites. Lipophilicity allows efficient crossing of the blood-brain barrier. Phospholipid complexes and nanoparticle formulations have been shown to enhance oral bioavailability by 1.5–3× in preclinical models. • **Macronutrients/micronutrients**: As an isolated alkaloid compound, TMP contains no significant macronutrients (protein, fat, carbohydrate, fiber), vitamins, or minerals. Caloric contribution is negligible at pharmacologically relevant doses (typically 20–120 mg in traditional preparations). • **Related bioactive co-occurring compounds (in source herb Ligusticum chuanxiong)**: Ferulic acid (~0.5–3 mg/g), senkyunolide A, Z-ligustilide (~2–10 mg/g), chuanxiongzine derivatives; these may exhibit synergistic cardiovascular and neuroprotective effects alongside TMP. • **Dosage context**: In traditional Chinese medicine injectable formulations, typical clinical doses are 40–120 mg IV; oral supplemental doses in research range from 100–400 mg/day, though human clinical trial data remain limited.
Tetramethylpyrazine exerts its effects through multiple pathways including free radical scavenging of superoxide anions and hydroxyl radicals, providing antioxidant protection. The compound inhibits platelet aggregation by interfering with thromboxane A2 synthesis and reduces blood viscosity through modulation of fibrinogen levels. Additionally, it demonstrates neuroprotective effects by reducing oxidative stress in neural tissue and potentially modulating calcium channel activity.
Current evidence for tetramethylpyrazine is limited to preclinical studies conducted in rodent models. Animal studies have shown neuroprotective effects against induced neurodegenerative conditions, with some studies demonstrating 20-40% reduction in neuronal damage markers. Cardiovascular research in laboratory settings indicates significant platelet aggregation inhibition and blood viscosity improvements. However, no human clinical trials have been conducted to validate these effects or establish safe and effective dosing protocols.
Safety data for tetramethylpyrazine in humans is extremely limited due to lack of clinical trials. The compound may potentially interact with anticoagulant medications due to its platelet aggregation inhibition effects, increasing bleeding risk. Individuals taking warfarin, heparin, or antiplatelet drugs should exercise caution. Pregnancy and breastfeeding safety has not been established, and use should be avoided during these periods.
